aaim diabetes workshop 2015 triennial...• t2d age onset < 20 or > 20 • between ages 25 –...
TRANSCRIPT
AAIM DIABETES WORKSHOP 2015 TRIENNIALRichard Braun, MD
John Kirkpatrick, MD
1
Topics for Discussion
• Type 1 Diabetes
• Type 2 Diabetes
• Children & adolescents
• Adults
• PreDiabetes
• Gestational Diabetes
• Morbidity & Mortality Considerations
2
Diabetes in the US
National Diabetes Statistics Report, 2014http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
3
Diabetes Prevalence
JAMA. 2015;314(10):1021-1029. doi:10.1001/jama.2015.10029
4
Diabetes - Pathogenesis
• Type 1 Diabetes (5-10% in US, Canada, Europe)
• 1A (85%) Insulin deficiency, caused by T-cell immune destruction of pancreatic beta cells – presence of pancreatic autoantibodies*
• 1B (15%) (idiopathic) non-autoimmune islet cell destruction & insulin deficiency
• Type 2 Diabetes (over 90% of cases in US, Canada, Europe)
• Hyperglycemia & insulin resistance with relative reduction of insulin secretion – usually lost ~ 80% of beta cell function by the time of diagnosis (Suggested by high fasting Insulin & C-peptides levels)
• Latent autoimmune diabetes in adults (LADA)
• Spectrum between Type 1 and type 2, sharing genetic features of both. Variable amounts of islet cell antibodies (ICA) and antibodies to glutamic acid decarboxylase (GAD) 65. Display quicker progression to insulin dependence.
*Auto Antibodies – ICA, GAD 65, tyrosine phosphotases, insulinoma-associated protein (IA-2) & IA-2 beta, and zinc transporter (ZnT8)
5
Diabetes - Pathogenesis• Monogenic Diabetes formerly Maturity Onset Diabetes of the Young
(MODY) – Accounts for 2-5% DM
6
MODY Types – Monogenic defects, Autosomal Dominant
Type Genetic defect Frequency Beta cell defectRisk of
microvascular disease
Optimal treatment
1
Hepatocyte nuclear
factor-4-alpha (HNF4A)
<10 percent
Reduced insulin
secretory response to glucose
Yes Sulfonylureas
2Glucokinase gene (GCK)
15 to 31 percent
Defective glucokinase
molecule (glucose sensor), increased plasma levels of glucose are necessary to elicit normal levels of insulin secretion
Generally no Diet
3Hepatocyte nuclear factor-1-alpha (HNF1A)
52 to 65 percentAbnormal insulin secretion, low renal threshold for glucose
Yes Sulfonylureas
4Insulin promoter factor 1 (IPF1)
Rare
Reduced binding to the insulin gene promoter, reduced activation of insulin gene in response to hyperglycemia
Yes
5Hepatocyte nuclear factor-1-beta (HNF1B)
Rare Yes Insulin
6Neurogenic differentiation factor-1 (NEUROD1 or BETA2)
RarePancreatic development
Yes Insulin
(modified)
Easy to confuse MODY with T2DM in the youngImportance is no insulin resistance (treatment), and family monitoring
7
Case
A 25 year-old woman applies for insurance. She was diagnosed with Type 1 Diabetes (T1DM) at age 9. She has had an insulin pump for about 12 years. She monitors her blood sugar 3 to 4 times daily and adjusts the pump dosing accordingly. She reports one or two hypoglycemic episodes per year. She is 5’7” tall and weighs 142 lbs. She has 2 children and is employed as a paralegal. She exercises regularly and has no other medical issues. Current Labs show an A1c of 7.2%, the urine is negative for albumin.
8
T1DM - Epidemiology
When individuals move, they assume the higher risk of the new location.Finland and Sardinia have 400 X the risk of Venezuela and parts of China.
9
T1DM – Epidemiology (US)• 75% occurs in children, 25 % in adults
• Bimodal incidence peaks, age 4-6 and 10-14; M:F – 3:2
• Incidence & prevalence increasing
JAMA. 2014;311(17):1778-1786.
10
Lifetime Risk of T1DM- Family Hx
Affected relative Lifetime risk
Mother 1-4%
Father 3-8%
Both Parents ~30%
Sibling (non-twin) 3-6%
Dizygotic (Fraternal)
twin
8%
Monozygotic (Identical)
twin
30% w/in 10 yrs, 65% by
age 60
11
Diagnosis T1DM
• Three presentations predominate
• Polyuria, polydipsia, weight loss
• Diabetic Ketoacidosis, add vomiting, lethargy (30%)
• Silent – being closely monitored
• Diagnostic Criteria
• Fasting Plasma Glucose > 125 mg/dl (7mmol/L)
• Random venous plasma glucose > 200 mg/dl (11.1 mmol/L)
• Oral glucose tolerance test (OGTT) – 2 hours after a 1.75 mg/kg (max 75g) glucose load – plasma glucose > 200 mg/dl (11.1 mmol/L)
• Glycated hemoglobin (A1C) > 6.5 percent
12
Treatment T1DMInsulinBalance of tight control And risk of hypoglycemic reactions- Adults A1C < 7 percent (53 mmol/mol)- Children < 7.5 % (59 mmol/mol)
A1C were > 7.5% in >70% of adolescents
Multiple Daily InjectionsInsulin PumpSensor augmented pump therapy
Artificial Beta cell - published on September 17, 2015, at NEJM.org- type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower A1C
level. (- .3 to .5)
13
T1DM and Life Expectancy
Men Women
Age Difference in
LE-Population
Percent of
2008 VBT
Difference in
LE-Population
Percent of
2008 VBT
20-24 11.1 yrs 300% 12.9 yrs ~350%
40-44 9.2 300% 10.8 ~350%
60-64 5.6 ~225% 7.1 ~300%
JAMA. 2015;313(1):37-44.
14
Copyright © 2015 American Medical Association. All rights reserved.
From: Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
JAMA. 2015;313(1):45-53.
doi:10.1001/jama.2014.16107
Cumulative Incidence of Mortality in the Diabetes Control and Complications TrialData are reported from the Diabetes Control and Complications Trial (DCCT; 1983-1993) and the subsequent observational follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study (1994 to December 31, 2012). Hazard ratios (HRs), CIs, and P values were obtained from a Cox proportional hazards model.
For men vs women, HR = 1.61 (95% CI, 1.09-2.39); P = .02; for the intensive vs conventional treatment groups (intent-to-treat analysis), HR = 0.67 (95% CI, 0.46-0.99); P = .045.
15
Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
JAMA. 2015;313(1):45-53.
doi:10.1001/jama.2014.16107
16
Copyright © 2015 American Medical Association. All rights reserved.
From: Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
JAMA. 2015;313(1):45-53. doi:10.1001/jama.2014.16107
Table - Separate Models of the Association of Each Time-Dependent Covariate With the Risk of Death and the Corresponding Death Rate Within Categories of Each Covariate
17
T1DM Mortality, Alleghany County, PA – 1965-79, Mean age onset 10.8 + 4.2
Diabetes Care 24:823–827, 2001
18
Pittsburgh Epidemiology of Diabetes Complications (EDC)Mean age at onset T1DM - 8.3
Life expectancy
At age 10 in 1965-80 – 58.8
Years;
Compared to
44.6 in 1950-64
Diabetes 61:2987–2992, 2012
19
Swedish experience survival after CABG with T1DM & T2DM
CABG at 58.8 years in T1DM
67.4 in T2DM
67.5 in non-DM
20
Case
• A 22 year-old male, non-smoker applies for life insurance. He is 6’1” tall and weighs 315 lbs, and has a BMI of 41.6. He passed out at a football practice in high school and was found to be dehydrated with glycosuria. Subsequent testing revealed an A1c of 7.1%. Family history was that his mother has hypertension and diabetes. He was diagnosed with Type 2 Diabetes (T2DM). He was started on Metformin at that time and A1c has ranged from 7.1% to 7.9%. The remainder of his laboratory tests are WNL. Efforts at weight loss have been unsuccessful, and he currently plays football at a Division II college.
21
T2DM in children and adolescents
JAMA. 2014;311(8):806-814.
22
T2DM in children and adolescents
National Diabetes Statistics Report, 2014http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
23
Mean BMI of Adults diagnosed with T2DM
24
T2DM in children and adolescents
Arch Pediatr Adolesc Med. 2008;162(7):682-687
- Lag time between obesity and T2DM ~ 10 years in PIMA Indians- Severity of Obesity related to onset of T2DM
25
Pediatric Diabetes Consortium• Characteristics of initial 503 patients with T2D
26
TODAY Study Group T2D
J Clin Endocrinol Metab 96: 159 –167, 2011
N Engl J Med 2012;366:2247-56.
65% Female, Mean Age 14,73% Hispanic or black
33.8% had HBP at avg F/U 3.9 yrs
27
Youth T2D• Not much data for long term study available
• Study in Pima Indians 1965-2002• T2D age onset < 20 or > 20
• Between ages 25 – 55 the age & sex adjusted rate of death from natural causes for youth onset disease was 15.4 per 1000 person-years, versus 7.3 deaths per 100 for older onset.
• Compared with non-diabetics the death rate for youth onset T2D was 3 times as high, and for older onset was 1.4 times as high.
• “The longer duration of diabetes largely accounts for these outcomes.”
JAMA. 2006;296:421-426
28
Intensive Control in T2DM
BMJ 2011;343:d4169 doi: 10.1136/bmj.d4169
29
BMJ 2011;343:d4169 doi: 10.1136/bmj.d4169
T2DM Intensive control
30
Kidney Disease measures & mortality with and without diabetes
Lancet. 2012 November 10; 380(9854): 1662–1673. doi:10.1016/S0140-6736(12)61350-6.
31
Case: T2DM
• 48 year old male• Dx: 8 months ago with T2DM
• Non smoker
• PMHx: HTN x 15 years
• FHx: Father MI at 54 (was a smoker)
• MEDS: Metformin 1000mg/d
• Lisinopril/HTCZ 20/25 qd
• PE: BMI 35
• BP 144/94
• Lipids • T Chol 280 mg/dL (15.6 mmol/L)
• HDL 40 mg/dL (2.2 mmol/L)
• Triglycerides 390 mg/dL (21.6 mmol/L)
• LDL not reported
• Fasting GLU 118 mg/dL (6.6 mmol/L)
• HgA1c 6.9%
32
The Emerging Risk Factors Collaboration. N EnglJ Med 2011;364:829-841.
Diabetes and Survival, According to Sex and Diabetes Status.
T2DM impact on life expectancy
Emerging Risk Factor Collaboration: T2DM without known vascular disease
The Emerging Risk Factors Collaboration. N Engl J Med 2011;364:829-841
6.3
6.8
5.8
6.4
4.5
5.4
0 2 4 6 8
40 yr Male
40 yr. Female
50 yr. Male
50 yr. Female
60 yr. Male
60 yr.Female
Years of Life Lost
34
Risk of Death: DM vs. non DM
• Death Hazard Ratio: DM vs. non
• All cause 1.80
• Renal Dz 3.02
• Coronary 2.31
• Liver 2.28
• Cancer 1.25
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathThe Emerging Risk Factors Collaboration N Engl J Med 2011;364:829-41.
• “In addition to vascular disease, diabetes is associated with substantial premature death from several cancers, infectious diseases, external causes, intentional self-harm, and degenerative disorders, independent of several major risk factors.”
35
T2DM : treated HTN
36
T2DM: add Albuminuria
• In the last year• 70 mg/g alb/creat
• (7.91 mg/mmol)
• 125 mg/g alb/creat• (14.13 mg/mmol)
• Our UA• 275 mg/g alb/creat
• (31.1 mg/mmol)
• Definitions• NORMAL
• ≤ 30 mg/g creat
• (3.4 mg/mmol creat)
• Microalbuminuria• 30-300 mg/g creat
• (3.4-34 mg/mmol)
• Macroalbuminuria• >300 mg/g
• (34 mg/mmol creat)
37
38
Renal Outcomes in T2DM
39
Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
Arch Intern Med. 2012 May 28;172(10):761-9
Kaplan-Meier plots of proportion of patients with microalbuminuria, macroalbuminuria, reduced creatinine clearance (CrCl), doubling of plasma creatinine, or any one of these, after
diagnosis of diabetes.
UKPDSRetnakaran R et al. Diabetes 2006;55:1832-1839
40
Impact of Nephropathy on Risk of Death41
UKPDS 64. Kidney International 2003; 63: 225-232
No nephropathy
Microalbuminuria
⇓⇓⇓⇓ 2.0%
Macroalbuminuria
⇓⇓⇓⇓ 2.8%
ESRD
⇓⇓⇓⇓ 2.3%
1%
3%
5%
19%
DEATH
Annual Risk
Risk of Death: DM vs. non DM• Death Hazard Ratio: DM vs. non
• All cause 1.80
• Renal Dz 3.02
• Coronary 2.31
• Liver 2.28
• Cancer 1.25
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathThe Emerging Risk Factors Collaboration N Engl J Med 2011;364:829-41.
• “In addition to vascular disease, diabetes is associated with substantial premature death from several cancers, infectious diseases, external causes, intentional self-harm, and degenerative disorders, independent of several major risk factors.”
42
Type 2 DiabetesWhat if: add Peripheral Neuropathy?
43
UKPDS
• At T2DM diagnosis
– 36% men
– 21% women
Had evidence of neuropathy
• At 12 years
– Of those free of any neuropathic abnormality
• 64% men
• 44% women
Developed at least one neuropathy endpoint
(vibratory sensory threshold, ankle jerk reflex, ED in males)
44
Multifactorial intervention and
CVD in patients with type 2 DMThe Steno-2 Study.P Gaede et al. N Engl J Med 348:
383, 2003
Peripheral Neuropathy
Vibratory sensory threshold
Ankle jerk reflexED in males
45
Diabetic Peripheral Neuropathy
Making the Diagnosis
Questionnaire
Michigan Neuropathy Screening Instrument
EMG
Neurothesiometer
32%
49%
79%
International Journal of Endocrinology. 2013
46
JAMA. 2015;314(10):1052-1062. doi:10.1001/jama.2015.9536
47
Pre-Diabetes
• 59 year old male $10 million policy
• BMI 26
• BP 120/82
• T Cholesterol 180 (10 mmol/L)
• GLU 94
• HgA1c 5.7%
• Exercises daily
• PMHx: two fasting GLU >100 (5.6 mmol/L)
• Without comment/follow up.
• No tobacco
• 13.5 METS on ETT
48
American Diabetes Associationwww.diabetes.org
Pre-Diabetes Definition
49
Diabetes Care. 2011 Mar; 34(3): 610–615.
Risk of T2DM by HgA1c
50
PLOS ONE | DOI:10.1371/journal.pone.0122698 April 8, 2015
Incidence of Type 2 Diabetes in Pre-DiabeticJapanese Individuals Categorized by HbA1c
Levels: A Historical Cohort Study
51
Hemaglobin A1c cut‐‐‐‐off point to identify a high risk group of future diabetes: Omiya MA Cohort Study
52
Diabetic Medicine 2012 Jul;29(7):905-910.
Gestational Diabetes
• 36 year old female
• Hx of Gestational Diabetes
• NSVD X 5, last one 8 months ago
• Rx: "shots” each pregnancy
• PE: BP 118/76
• BMI 38
• Ginger 1 gm TID
• Script check: negative
• Cotinine negative by oral fluid
53
54
Gestational Diabetes: Definitions
OVERT DIABETES GESTATIONALDIABETES
• FPG ≥ 126 mg/dL(7.0 mmol/L)
• A1C ≥ 6.5 %
• Random GLU ≥ 200
• (11.1 mmol/L)
� FPG ≥ 92 (5.1 mmol/L)
� At 24-28 weeks
� 75 gm 2 hour GTT
� At least one of the following:
FPG: ≥ 92 mg/dL (5.1 mmol/L) but
≤ 126 mg/dl (7.0 mmol/L)
1 HOUR: ≥ 180 mg/dL (10.0 mmol/L)
2 HOUR: ≥ 153 mg/dL (8.5 mmol/L)
2010 International Association of Diabetes and Pregnancy Study Group2011 American Diabetes Association
Gestational Diabetes
• 10% either T2DM or Latent Type 1
• 1/3-2/3 GDM in subsequent pregnancy
• 20% IGT post partum
• Risk of T2DM
• 20-60%in next 10 years
• 50-75% if BMI > 30
• RR 4.69 at 5 yrs.
• RR 9.34 > 5 yrs.
55
www.cdc.gov/diabetes